DBV Technologies (NASDAQ:DBVT) Share Price Passes Below Two Hundred Day Moving Average – Should You Sell?

DBV Technologies S.A. (NASDAQ:DBVT)’s share price crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $17.94 and traded as low as $13.40. DBV Technologies shares last traded at $13.61, with a volume of 185,679 shares traded.

Analyst Ratings Changes

A number of research firms have issued reports on DBVT. Citizens Jmp upped their target price on shares of DBV Technologies from $47.00 to $55.00 and gave the company a “market outperform” rating in a report on Tuesday, June 30th. Wall Street Zen lowered shares of DBV Technologies from a “hold” rating to a “sell” rating in a research report on Saturday, July 4th. Weiss Ratings downgraded shares of DBV Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, July 17th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of DBV Technologies in a research note on Tuesday, June 30th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $48.50.

DBV Technologies Stock Performance

The company has a market cap of $849.51 million, a price-to-earnings ratio of -3.88 and a beta of -0.95. The stock’s fifty day simple moving average is $14.63 and its two-hundred day simple moving average is $17.89.

Institutional Investors Weigh In On DBV Technologies

Institutional investors have recently added to or reduced their stakes in the company. Perceptive Advisors LLC purchased a new stake in shares of DBV Technologies during the 1st quarter worth about $20,146,000. Vivo Capital LLC raised its holdings in DBV Technologies by 8.4% in the first quarter. Vivo Capital LLC now owns 2,667,569 shares of the company’s stock valued at $55,726,000 after buying an additional 205,943 shares during the period. ADAR1 Capital Management LLC acquired a new position in DBV Technologies during the first quarter valued at approximately $21,159,000. Royal Bank of Canada lifted its position in DBV Technologies by 167.1% during the first quarter. Royal Bank of Canada now owns 4,680 shares of the company’s stock valued at $98,000 after buying an additional 2,928 shares in the last quarter. Finally, Elmind Capital LP acquired a new position in DBV Technologies during the first quarter valued at approximately $5,536,000. Hedge funds and other institutional investors own 71.74% of the company’s stock.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.